Live Breaking News & Updates on Takeda Tak861 Orexin Receptor 2 Ox2r Narcolepsy Type 1 Nct05687903 Nct05687916 Nt1 Nt2 Maintenance Of Wakefulness Test Epworth Sleepiness Scale Weekly Cataplexy Rate Sarah Sheikh Gastrointestinal Inflammation Rare Diseases Plasmaderived Therapies Oncology Neuroscience Vaccines

Stay updated with breaking news from Takeda tak861 orexin receptor 2 ox2r narcolepsy type 1 nct05687903 nct05687916 nt1 nt2 maintenance of wakefulness test epworth sleepiness scale weekly cataplexy rate sarah sheikh gastrointestinal inflammation rare diseases plasmaderived therapies oncology neuroscience vaccines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK861 an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1. ....

United States , Yuko Yoneyama , Takeda Pharmaceutical Company Limited , Exchange Commission , Upcoming Scientific Congress , Key Secondary Endpoints Were Met , Narcolepsy Type , Generally Safe , Results Will , Upcoming Scientific , Wakefulness Test , Annual Report , Media Contact , Takeda Tak861 Orexin Receptor 2 Ox2r Narcolepsy Type 1 Nct05687903 Nct05687916 Nt1 Nt2 Maintenance Of Wakefulness Test Epworth Sleepiness Scale Weekly Cataplexy Rate Sarah Sheikh Gastrointestinal Inflammation Rare Diseases Plasmaderived Therapies Oncology Neuroscience Vaccines ,